RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer

Breast Cancer Research and Treatment

Volumn 105, Issue 1, 2007, Pages 7-16

  Lau, Y S ^a   Danks, L ^a   Sun, S G ^b   Fox, S ^c   Sabokbar, A ^a   Harris, A ^c   Athanasou, N A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Bone resorption; Breast cancer; Osteoclast; RANKL

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; FC RECEPTOR; GROWTH FACTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BONE CELL; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL STIMULATION; CELL STRAIN MCF 7; COCULTURE; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; STROMA CELL;

AGED; BONE AND BONES; BREAST NEOPLASMS; CELL DIFFERENTIATION; DNA PRIMERS; FEMALE; FIBROBLASTS; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MIDDLE AGED; MODELS, BIOLOGICAL; OSTEOCLASTS; RANK LIGAND; STROMAL CELLS;

EID: 34548033715     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9438-y     Document Type: Article

References (41)

1. Stoll BA (1983) Natural history, prognosis and staging of bone metastases. In: Stoll BA, Parbhoo S (eds) Bone metastases: monitoring and treatment. Raven Press, New York, pp 1-4
2. Clohisy DR, Palkert D, Ramnaraine ML, Pekurovsky I, Oursler MJ (1996) Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. J Orthop Res 14:396-402
3. Mundy GR (1991) Mechanisms of osteolytic bone destruction. Bone 12:51-56
4. Blair HC, Athanasou NA (2004) Recent advances in osteoclast biology. Histol and Histopathol 19:189-199
5. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA (1996) The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058-4060
6. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
7. Hofbauer LC, Khosla S, Dunstan C, Lacey DL, Boyle W, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Bone Min Res 15:2-12
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ, et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
9. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451-4458
10. Itonaga I, Kudo O, Sabokbar A, Danks L, Ferguson D, Fujikawa Y, Athanasou NA (2004) Transforming growth factor β induces human osteoclast formation. Bone 34:57-64
11. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275-286
12. Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA (2002) Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol 198:220-227
13. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA (2003) Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32:1-7
14. Bugelski PJ, Corwin SP, North SM, Kirsh RL, Nicolson GL, Poste G (1987) Macrophage content of spontaneous metastases at different stages of growth. Cancer Res 47:4141-4145
15. Van Ravenswaay Classen HH, Kluin PM, Fleuren G (1992) Tumour infiltrating cells in human cancer: on the possible role of CD16+ macrophages in anti-tumour cytoxicity. Lab Invest 67:166-174
16. Quinn JM, Athanasou NA, McGee JO'D (1992) Tumour infiltrating macrophages are capable of bone resorption. J Cell Science 101:681-686
17. Quinn J, Matsumura Y, Tarin D, McGee JO'D, Athanasou NA (1994) Cellular and hormonal mechanisms associated with malignant bone resorption. Lab Invest 71:465-471
18. Hunt N, Fujikawa Y, Itonaga I, Harris A, Athanasou NA (2001) Cellular mechanisms of bone resorption in breast cancer. Br J Cancer 85:78-84
19. Quinn JMW, McGee JO'D, Athanasou NA (1998) Human tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells. J Pathol 184:31-36
20. Athanasou NA, Quinn J (1990) Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 43:997-1003
21. Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34:285-290
22. Davies J, Warwick J, Totty N, Philp R, Helfrich M, Horton M (1989) The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 109:1817-1826
23. Gundle R, Beresford JN (1995) The isolation and culture of cells from explants of human trabecular bone. Calcif Tissue Int 56:8-10
24. Sun SG, Lau YS, Itonaga I, Sabokbar A, Athanasou NA (2006) Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. J Pathol 209(1):114-120
25. Bugelski PJ, Kirsh RL, Sowinski JM, Poste GL (1985) Changes in the macrophage content of lung metastases at different stages in tumor growth. Am J Pathol 118:419-424
26. Normann SJ (1985) Macrophage infiltration and tumour progression. Cancer Metastasis Rev 4:227-291
27. Galasko CBS (1976) Mechanisms of bone destruction in the development of skeletal metastasis. Nature 276:726-728
28. Mantovani A (1994) Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 71:5-16
29. Yamashiro S, Takaya M, Nishi T, Kuratsu J, Yashimura T, Usho Y, Takahashi K (1994) Tumor-derived monocyte chemoattractant protein induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumour. Am J Pathol 145:856-867
30. Yoshimura T, Takeya M, Takahashi K (1991) Molecular cloning of rat monocyte chemoattractant protein-1 (MCP-1) and its expression in rat spleen cells and tumour cell lines. Biochem Biophys Res Commun 174:504-509
31. Flanagan AM, Lader CS (1998) Update on the biologic effects of macrophage-colony stimulating factor. Curr Opinion Hematol 5:181-185
32. Faust J, Lacey DL, Hunt P, Burgess TL, Scully S, Van G, Eli A, Qian Y, Shalhoub V (1999) Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem 72:67-80
33. Quinn JWM, Elliott J, Gillespie MT, Martin TJ (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation. Endocrinology 139:4424-4427
34. Massey HM, Flanagan AM (1999) Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 106:167-170
35. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ (2000) Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res 15:1459-1466
36. Sabokbar A, Itonaga I, Sun SG, Kudo O, Athanasou NA (2005) Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. J Orthop Res 23:511-519
37. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259-269
38. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, Diprinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367
39. Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE, Holen I (2006) Espression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol 59:56-63
40. Pederson L, Winding B, Foged NT (1999) Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 59:5849-5855
41. Lau YS, Sabokbar A, Giele H, Cerundolo V, Hofstetter W, Athanasou NA (2006) Malignant melanoma and bone resorption. Br J Cancer 94:1496-503